SAGE Therapeutics (NASDAQ:SAGE) Stock Price Up 5.4%

Share on StockTwits

SAGE Therapeutics Inc (NASDAQ:SAGE)’s share price rose 5.4% during trading on Friday . The stock traded as high as $147.17 and last traded at $146.40, approximately 326,529 shares were traded during trading. A decline of 31% from the average daily volume of 470,055 shares. The stock had previously closed at $138.93.

Several research firms recently issued reports on SAGE. HC Wainwright began coverage on SAGE Therapeutics in a research report on Wednesday, October 30th. They set a “neutral” rating and a $160.00 price target on the stock. ValuEngine upgraded SAGE Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BidaskClub lowered SAGE Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, November 1st. Oppenheimer reduced their price target on SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $187.78.

The firm has a 50-day moving average of $143.81 and a 200-day moving average of $164.16. The firm has a market capitalization of $7.46 billion, a P/E ratio of -18.12 and a beta of 2.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 16.00 and a current ratio of 16.00.

In other SAGE Therapeutics news, Director James M. Frates sold 8,000 shares of SAGE Therapeutics stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $160.58, for a total value of $1,284,640.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 4.60% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of SAGE. Amundi Pioneer Asset Management Inc. increased its holdings in shares of SAGE Therapeutics by 40.7% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 136,459 shares of the biopharmaceutical company’s stock worth $21,704,000 after purchasing an additional 39,447 shares in the last quarter. First American Trust FSB grew its holdings in shares of SAGE Therapeutics by 2.4% in the second quarter. First American Trust FSB now owns 17,854 shares of the biopharmaceutical company’s stock worth $3,269,000 after acquiring an additional 419 shares during the period. EFG Asset Management Americas Corp. grew its holdings in shares of SAGE Therapeutics by 1.2% in the second quarter. EFG Asset Management Americas Corp. now owns 20,433 shares of the biopharmaceutical company’s stock worth $3,741,000 after acquiring an additional 244 shares during the period. Chicago Capital LLC grew its holdings in shares of SAGE Therapeutics by 0.6% in the second quarter. Chicago Capital LLC now owns 73,439 shares of the biopharmaceutical company’s stock worth $13,446,000 after acquiring an additional 416 shares during the period. Finally, Xact Kapitalforvaltning AB grew its holdings in shares of SAGE Therapeutics by 14.0% in the second quarter. Xact Kapitalforvaltning AB now owns 8,144 shares of the biopharmaceutical company’s stock worth $1,491,000 after acquiring an additional 1,000 shares during the period.

About SAGE Therapeutics (NASDAQ:SAGE)

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

Featured Article: What is a front-end load?

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Goelzer Investment Management Inc. Purchases New Position in Globe Life Inc.
Goelzer Investment Management Inc. Purchases New Position in Globe Life Inc.
Systematic Financial Management LP Has $621,000 Stock Holdings in Synovus Financial Corp.
Systematic Financial Management LP Has $621,000 Stock Holdings in Synovus Financial Corp.
Boeing Co  Stock Holdings Lessened by Goelzer Investment Management Inc.
Boeing Co Stock Holdings Lessened by Goelzer Investment Management Inc.
Goelzer Investment Management Inc. Has $3.26 Million Stock Position in Hanover Insurance Group Inc
Goelzer Investment Management Inc. Has $3.26 Million Stock Position in Hanover Insurance Group Inc
Insight Wealth Strategies LLC Acquires Shares of 1,830 Vanguard Dividend Appreciation ETF
Insight Wealth Strategies LLC Acquires Shares of 1,830 Vanguard Dividend Appreciation ETF
Insight Wealth Strategies LLC Has $279,000 Holdings in Lowe’s Companies, Inc.
Insight Wealth Strategies LLC Has $279,000 Holdings in Lowe’s Companies, Inc.


 
© 2006-2019 Zolmax.